company background image
ADVM logo

Adverum Biotechnologies NasdaqCM:ADVM Stock Report

Last Price

US$2.00

Market Cap

US$414.3m

7D

-1.5%

1Y

185.7%

Updated

26 Feb, 2024

Data

Company Financials +

Adverum Biotechnologies, Inc.

NasdaqCM:ADVM Stock Report

Market Cap: US$414.3m

ADVM Stock Overview

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases.

ADVM fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Adverum Biotechnologies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share PriceUS$2.00
52 Week HighUS$2.97
52 Week LowUS$0.68
Beta0.70
1 Month Change112.88%
3 Month Change144.14%
1 Year Change185.71%
3 Year Change-84.99%
5 Year Change-59.35%
Change since IPO-92.05%

Recent News & Updates

Recent updates

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Feb 24
We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Sep 07
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Aug 11

Adverum gains 13% to reach three-month high after Truist upgrade

Jul 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

May 12
We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Jul 17
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Adverum Biotechnologies: An Uncertain Path Forward

May 05

Adverum Bio presents long-term data from ADVM-022 trial in wet AMD

May 03

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Apr 06
We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Feb 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

Adverum highlights preclinical long-term safety data on ADVM-022 IVT gene therapy

Feb 02

Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Jan 22
Trade Alert: The Independent Chairman Of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), C. Machado, Has Just Spent US$115k Buying 15% More Shares

Adverum In Wet AMD And Diabetic Macular Edema: Playing In A Differentiated Market

Jan 11

Adverum Biotechnologies announces new GMP gene therapy manufacturing facility

Jan 07

How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Dec 31
How Much Are Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Insiders Spending On Buying Shares?

Adverum ticks lower on underwhelming data from gene therapy in wet-AMD

Nov 16

Shareholder Returns

ADVMUS BiotechsUS Market
7D-1.5%1.5%1.3%
1Y185.7%10.5%25.6%

Return vs Industry: ADVM exceeded the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: ADVM exceeded the US Market which returned 25.6% over the past year.

Price Volatility

Is ADVM's price volatile compared to industry and market?
ADVM volatility
ADVM Average Weekly Movement21.3%
Biotechs Industry Average Movement11.4%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ADVM's share price has been volatile over the past 3 months.

Volatility Over Time: ADVM's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006123Laurent Fischerhttps://adverum.com

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection.

Adverum Biotechnologies, Inc. Fundamentals Summary

How do Adverum Biotechnologies's earnings and revenue compare to its market cap?
ADVM fundamental statistics
Market capUS$414.33m
Earnings (TTM)-US$126.19m
Revenue (TTM)US$3.60m

115.1x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADVM income statement (TTM)
RevenueUS$3.60m
Cost of RevenueUS$82.91m
Gross Profit-US$79.31m
Other ExpensesUS$46.88m
Earnings-US$126.19m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.61
Gross Margin-2,203.00%
Net Profit Margin-3,505.19%
Debt/Equity Ratio0%

How did ADVM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.